AZSTARYS
Drug
Corium, LLC
Total Payments
$7.4M
Transactions
49,358
Doctors
17,252
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.5M | 1,247 | 627 |
| 2023 | $1.9M | 1,220 | 843 |
| 2022 | $2.1M | 46,452 | 16,373 |
| 2021 | $14,395 | 439 | 288 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.0M | 354 | 67.9% |
| Food and Beverage | $1.0M | 47,797 | 13.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $882,320 | 345 | 11.9% |
| Consulting Fee | $318,313 | 146 | 4.3% |
| Travel and Lodging | $175,259 | 716 | 2.4% |
Payments by Type
Research
$5.0M
354 transactions
General
$2.4M
49,004 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Efficacy and Safety Study w/ Azstarys in Children With ADHD | Corium, LLC | $1.7M | 0 |
| An Efficacy and Safety Study w/? Azstarys in Children With ADHD | Corium, LLC | $1.4M | 0 |
| A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | Corium, LLC | $1.4M | 0 |
| A Safety/Tolerability and PK Study With Azstarys in Children With ADHD | Corium, LLC | $269,726 | 0 |
| Placebo-Controlled Double-Blind Study to Determine the Safety and Efficacy of SDX in Patients With IH | Zevra Therapeutics Inc | $133,136 | 0 |
| AN OPEN-LABEL, TREATMENT, INVESTIGATOR-INITIATED STUDY, ON THE DURATION AND EFFICACY OF AZSTARYS SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE) ON ADULT ADHD SYMPTOMS AND EXECUTIVE FUNCTION THROUGHOUT THE DAY INTO EARLY EVENING | Corium, LLC | $131,153 | 0 |
| Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH | Zevra Therapeutics Inc | $8,199 | 0 |
Top Doctors Receiving Payments for AZSTARYS — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Psychiatry | Carmel, IN | $3,843 | 19 |
| , M.D | Adolescent Medicine | Barling, AR | $3,744 | 8 |
| , M.D | Psychiatry | Shreveport, LA | $3,716 | 7 |
| Jeffrey Richmond | Psychiatry | Denver, CO | $3,683 | 5 |
| , MD | Psychiatry | Charleston, SC | $3,532 | 2 |
| , M.D | Pediatrics | Rockville, MD | $3,304 | 6 |
| , M.D | Addiction Psychiatry | Dallas, TX | $3,220 | 6 |
| , MD | Family Medicine | Lake Charles, LA | $3,092 | 2 |
| , M.D | Psychiatry | Milwaukee, WI | $2,725 | 5 |
| , PMHNP-BC | Registered Nurse | Bend, OR | $2,162 | 7 |
| , DNP, PMHNP-BC, RN | Psychiatric/Mental Health | Troy, AL | $2,154 | 8 |
| , M.D | Psychiatry | Racine, WI | $2,130 | 3 |
| , MD | Pediatrics | Norcross, GA | $1,846 | 3 |
| , MD | Psychiatry | Bellaire, TX | $1,790 | 24 |
| , M.D | Specialist | Encino, CA | $1,545 | 3 |
| , M.D | Child & Adolescent Psychiatry | Dallas, TX | $1,538 | 5 |
| , MD | Pediatrics | Kernersville, NC | $1,492 | 2 |
| , MD | Neurology | Aventura, FL | $1,462 | 4 |
| , PMHNP-BC | Psychiatric/Mental Health | Bradford, RI | $1,419 | 8 |
| , PMHNP | Psychiatric/Mental Health | Brentwood, MO | $1,090 | 10 |
| , M.D | Psychiatry | Amherst, NY | $1,045 | 6 |
| , PMHNP | Psychiatric/Mental Health | Weldon Spring, MO | $956.22 | 6 |
| , PMHNP-BC | Psychiatric/Mental Health | Brentwood, MO | $953.70 | 6 |
| , MD | Geriatric Psychiatry | Rochester, NY | $912.31 | 5 |
| , NURSE PRACTIONER | Psychiatric/Mental Health | Mckinney, TX | $872.71 | 3 |
Ad
Manufacturing Companies
- Corium, LLC $7.3M
- Zevra Therapeutics Inc $141,335
Product Information
- Type Drug
- Total Payments $7.4M
- Total Doctors 17,252
- Transactions 49,358
About AZSTARYS
AZSTARYS is a drug associated with $7.4M in payments to 17,252 healthcare providers, recorded across 49,358 transactions in the CMS Open Payments database. The primary manufacturer is Corium, LLC.
Payment data is available from 2021 to 2024. In 2024, $3.5M was paid across 1,247 transactions to 627 doctors.
The most common payment nature for AZSTARYS is "Unspecified" ($5.0M, 67.9% of total).
AZSTARYS is associated with 7 research studies, including "An Efficacy and Safety Study w/ Azstarys in Children With ADHD" ($1.7M).